SCHEMBL6162470

SCHEMBL6162470

COCc1ccnc(N)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 3/20 0.44
HRH4 Q9H3N8 2/20 0.41
HRH3 Q9Y5N1 4/20 0.41
CCNT1 O60563 2/20 0.40
CDK9 P50750 2/20 0.40
CDK5 Q00535 2/20 0.40
CDK5R1 Q15078 2/20 0.40
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PI4KA P42356 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
TLR8 Q9NR97 1/20 0.39
LMNA P02545 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CCNA1 P78396 1/20 0.38
HSP90AA1 P07900 2/20 0.37
AURKA O14965 1/20 0.37
PRKACA P17612 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17397384 0.81 CDK5 (0.44) NUDT1HRH4HRH3CCNT1CDK9
SCHEMBL9195323 0.78 LMNA (0.43) LMNA
SCHEMBL4274947 0.78 RXRA (0.40) PIK3CDPIK3CAPIK3CBPI4KAPI4KB
SCHEMBL241319 0.77
SCHEMBL1347059 0.77 NUDT1 (0.39) NUDT1HRH4HRH3TLR8
SCHEMBL1785770 0.77 NUDT1 (0.46) NUDT1HRH4HRH3CCNT1CDK9
SCHEMBL24982790 0.76 S1PR4 (0.43) LMNA
SCHEMBL24921742 0.74 RXRA (0.39) PIK3CDPIK3CAPIK3CBPI4KAPI4KB
SCHEMBL24921778 0.74 RXRA (0.38) PIK3CDPIK3CAPIK3CBPI4KAPI4KB
SCHEMBL17379406 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0977545-B1 THE USE OF 1-SUBSTITUTED ISATINS TO DYE FIBERS CONTAINING KERATIN HENKEL KGAA (DE) 2005-02-16 EP claimed
WO-2025076284-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME DELPHIA THERAPEUTICS, INC. (US) 2025-04-10 WO disclosed
CN-114245796-B Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of diseases 比奥根MA公司 2024-07-30 CN disclosed
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. 2023-03-23 US disclosed
WO-2023006097-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-02-02 WO disclosed
EP-3990454-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE Biogen MA Inc. (US) 2022-05-04 EP disclosed
CN-114245796-A Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of disease 比奥根MA公司 2022-03-25 CN disclosed
WO-2020263980-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. (US) 2020-12-30 WO disclosed
US-9926333-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2018-03-27 US disclosed
US-20170327514-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2017-11-16 US disclosed
US-9732093-B2 FLAP modulators JANSSEN PHARMACEUTICA NV (BE) 2017-08-15 US disclosed
US-20150368270-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-12-24 US disclosed
US-20150252008-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-09-10 US disclosed
US-9073876-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2015-07-07 US disclosed
US-20140221310-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 US disclosed
US-20070105832-A1 Substituted azetidinones Cadrenal Therapeutics, Inc. 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105832-A1 Substituted azetidinones F2R, CPA3, CFD NUDT1 4213/4885HRH4 175/4885HRH3 240/4885
US-20170327514-A1 FLAP MODULATORS FEN1, PGF, TBXA2R NUDT1 1176/4885HRH4 2261/4885HRH3 2530/4885
US-20140221310-A1 FLAP MODULATORS FEN1, PGF, PTGIS NUDT1 1362/4885HRH4 2486/4885HRH3 2648/4885
US-20150368270-A1 FLAP MODULATORS FEN1, PGF, TBXA2R NUDT1 1176/4885HRH4 2261/4885HRH3 2530/4885
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE IRAK4, IRAK2, IRAK1 NUDT1 3145/4885HRH4 724/4885HRH3 2187/4885
US-20150252008-A1 FLAP MODULATORS FEN1, PGF, PTGIS NUDT1 1362/4885HRH4 2486/4885HRH3 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.